Figure 3.

(A) MMP2 and (B) MMP3 multiplex protein concentration (pg/10⁵ cells) after 14-days treatment with vehicle (V) or 10 nM estradiol (E₂), or 10 nM E₂ plus 1 µM progesterone (E₂P₄). DCtrl, eSF from controls; dPCOS, eSF from women with PCOS (8/12) that exhibit decidualization; ndPCOS, eSF from women with PCOS (4/12) that did not decidualize. The significant differences (P < 0.05) are marked as follows: − (line) between the different treatment groups within the study group (dCtrl or dPCOS or ndPCOS) and * (asterisk) compared with dCtrl and † (cross) compared with dPCOS in the same treatment group between different study groups.